<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227395</url>
  </required_header>
  <id_info>
    <org_study_id>A0661097</org_study_id>
    <nct_id>NCT01227395</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients</brief_title>
  <official_title>Drug Use Investigation On Zithromac Tablets 600mg In HIV Patients (Post Marketing Commitment Plan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Altmarc Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigation will be conducted for the purpose of determining the condition of
      occurrence of Adverse Events under the actual post-marketing use of Zithromac 600mg Tablet,
      verifying the therapeutic effects, detecting unknown Adverse Drug Reactions and drug
      interactions and determining the factors affecting safety and efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients whom an investigator prescribes the first Zithromac Tablets 600mg should be
      registered consecutively until the number of subjects reaches target number in order to
      extract patients enrolled into the investigation at random.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With the Frequency of Treatment Related Adverse Events.</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Adverse events mean all unfavorable events that occur in participants after administration of Azithromycin, irrespective of causal relationship to Azithromycin (including clinically problematic abnormal changes in laboratory test values). Treatment related Adverse Events were evaluated in company with the causal relationship to Azithromycin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Unlisted Treatment Related Adverse Events in Japanese Package Insert.</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Adverse events mean all unfavorable events that occur in participants after administration of Azithromycin, irrespective of causal relationship to Azithromycin (including clinically problematic abnormal changes in laboratory test values). Number of Treatment Related Adverse Events were evaluated in company with the causal relationship to Azithromycin. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events -Age (Prophylaxis).</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether &lt;65 years or &gt;=65 years is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events -Gender (Prophylaxis).</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether male or female is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events -Concomitant Drugs (Prophylaxis).</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether with or without concomitant drugs is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events -Renal Dysfunction (Prophylaxis).</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without renal dysfunction is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events -Allergies (Prophylaxis).</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without allergies is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events -Age (Treatment).</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether &lt;65 years or &gt;=65 years is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events -Gender (Treatment).</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether male or female is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events -Renal Dysfunction (Treatment).</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without renal dysfunction is significant risk factor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk Factors for the Frequency of Treatment Related Adverse Events -Allergies (Treatment).</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without allergies is significant risk factor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Responded to Azithromycin Treatment.</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Prevented by Azithromycin Treatment.</measure>
    <time_frame>9 years(MAX)</time_frame>
    <description>The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">476</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <description>Patients taking Azithromycin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.
Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults.</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>Zithromac, Zithromax, Azithromycin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects whom an investigator involving A0661097 prescribes the Azithromycin Tablets
        600mg (Zithromac Tablets 600mg).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients need to be administered Zithromac Tablets 600mg in order to be enrolled in the
        surveillance.

        Exclusion Criteria:

        Patients not administered Zithromac Tablets 600mg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0661097&amp;StudyName=Drug%20Use%20Investigation%20On%20Zithromac%20%28Azithromycin%29%20In%20HIV%20Patients%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <results_first_submitted>March 4, 2013</results_first_submitted>
  <results_first_submitted_qc>March 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2013</results_first_posted>
  <last_update_submitted>April 18, 2013</last_update_submitted>
  <last_update_submitted_qc>April 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Post Marketing Surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a phase 4, observational, open-label study conducted in participants who were prescribed azithromycin by their treating physician per usual clinical practice. Study drug was not provided by the Sponsor.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Azithromycin for Prophylaxis</title>
          <description>Participants taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
        </group>
        <group group_id="P2">
          <title>Azithromycin for Treatment</title>
          <description>Participants taking Azithromycin for Treatment according to Japanese Package Insert.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="391"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="391"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azithromycin for Prophylaxis</title>
          <description>Participants taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
        </group>
        <group group_id="B2">
          <title>Azithromycin for Treatment</title>
          <description>Participants taking Azithromycin for Treatment according to Japanese Package Insert.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="391"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="475"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="381"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="360"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Frequency of Treatment Related Adverse Events.</title>
        <description>Adverse events mean all unfavorable events that occur in participants after administration of Azithromycin, irrespective of causal relationship to Azithromycin (including clinically problematic abnormal changes in laboratory test values). Treatment related Adverse Events were evaluated in company with the causal relationship to Azithromycin.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>No statistical analysis provided for the frequency of treatment related adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin for Prophylaxis</title>
            <description>Participants taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin for Treatment</title>
            <description>Participants taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Frequency of Treatment Related Adverse Events.</title>
          <description>Adverse events mean all unfavorable events that occur in participants after administration of Azithromycin, irrespective of causal relationship to Azithromycin (including clinically problematic abnormal changes in laboratory test values). Treatment related Adverse Events were evaluated in company with the causal relationship to Azithromycin.</description>
          <population>No statistical analysis provided for the frequency of treatment related adverse events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Unlisted Treatment Related Adverse Events in Japanese Package Insert.</title>
        <description>Adverse events mean all unfavorable events that occur in participants after administration of Azithromycin, irrespective of causal relationship to Azithromycin (including clinically problematic abnormal changes in laboratory test values). Number of Treatment Related Adverse Events were evaluated in company with the causal relationship to Azithromycin. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>No statistical analysis provided for the number of the unlisted treatment related adverse events in Japanese Package Insert.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin for Prophylaxis</title>
            <description>Participants taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin for Treatment</title>
            <description>Participants taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unlisted Treatment Related Adverse Events in Japanese Package Insert.</title>
          <description>Adverse events mean all unfavorable events that occur in participants after administration of Azithromycin, irrespective of causal relationship to Azithromycin (including clinically problematic abnormal changes in laboratory test values). Number of Treatment Related Adverse Events were evaluated in company with the causal relationship to Azithromycin. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert.</description>
          <population>No statistical analysis provided for the number of the unlisted treatment related adverse events in Japanese Package Insert.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Age (Prophylaxis).</title>
        <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether &lt;65 years or &gt;=65 years is significant risk factor.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>&lt;65 Years</title>
            <description>Participants with &lt;65 years who taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>&gt;=65 Years</title>
            <description>Participants with &gt;=65 years who taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Age (Prophylaxis).</title>
          <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether &lt;65 years or &gt;=65 years is significant risk factor.</description>
          <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Age&quot;. The null hypothesis is there is no difference between &quot;&lt;65 years and &gt;=65 years &quot; in the frequency of Treatment Related Adverse Events(TRAEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.696</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Gender (Prophylaxis).</title>
        <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether male or female is significant risk factor.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Male</title>
            <description>Male Participants taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Female</title>
            <description>Female Participants taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Gender (Prophylaxis).</title>
          <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether male or female is significant risk factor.</description>
          <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="360"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Gender&quot;. The null hypothesis is there is no difference between &quot;Male and Female &quot; in the frequency of Treatment Related Adverse Events(TRAEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.334</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Concomitant Drugs (Prophylaxis).</title>
        <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether with or without concomitant drugs is significant risk factor.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drugs was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin With Concomitant Drugs</title>
            <description>Participants with concomitant drugs who taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin Without Concomitant Drugs</title>
            <description>Participants without concomitant drugs who taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Concomitant Drugs (Prophylaxis).</title>
          <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether with or without concomitant drugs is significant risk factor.</description>
          <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drugs was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;concomitant drugs&quot;. The null hypothesis is there is no difference between &quot;with and without concomitant drugs &quot; in the frequency of Treatment Related Adverse Events(TRAEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Renal Dysfunction (Prophylaxis).</title>
        <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without renal dysfunction is significant risk factor.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin With Renal Dysfunction</title>
            <description>Participants with renal dysfunction who taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin Without Renal Dysfunction</title>
            <description>Participants without renal dysfunction who taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Renal Dysfunction (Prophylaxis).</title>
          <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without renal dysfunction is significant risk factor.</description>
          <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Renal Dysfunction&quot;. The null hypothesis is there is no difference between &quot;with and without renal dysfunction &quot; in the frequency of Treatment Related Adverse Events(TRAEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Allergies (Prophylaxis).</title>
        <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without allergies is significant risk factor.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin With Allergies</title>
            <description>Participants with allergies who taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin Without Allergies</title>
            <description>Participants without allergies who taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Allergies (Prophylaxis).</title>
          <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without allergies is significant risk factor.</description>
          <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Allergies&quot;. The null hypothesis is there is no difference between &quot;with and without allergies&quot; in the frequency of Treatment Related Adverse Events(TRAEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.015</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Age (Treatment).</title>
        <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether &lt;65 years or &gt;=65 years is significant risk factor.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>&lt;65 Years</title>
            <description>Participants with &lt;65 years who taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>&gt;=65 Years</title>
            <description>Participants with &gt;=65 years who taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Age (Treatment).</title>
          <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether &lt;65 years or &gt;=65 years is significant risk factor.</description>
          <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Age&quot;. The null hypothesis is there is no difference between &quot;&lt;65 years and &gt;=65 years &quot; in the frequency of Treatment Related Adverse Events(TRAEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Gender (Treatment).</title>
        <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether male or female is significant risk factor.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Male</title>
            <description>Male Participants taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Female</title>
            <description>Female Participants taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Gender (Treatment).</title>
          <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin Tablets to determine whether male or female is significant risk factor.</description>
          <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Gender&quot;. The null hypothesis is there is no difference between &quot;Male and Female &quot; in the frequency of Treatment Related Adverse Events(TRAEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.290</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Renal Dysfunction (Treatment).</title>
        <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without renal dysfunction is significant risk factor.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin With Renal Dysfunction</title>
            <description>Participants with renal dysfunction who taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin Without Renal Dysfunction</title>
            <description>Participants without renal dysfunction who taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Renal Dysfunction (Treatment).</title>
          <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without renal dysfunction is significant risk factor.</description>
          <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Renal Dysfunction&quot;. The null hypothesis is there is no difference between &quot;with and without renal dysfunction &quot; in the frequency of Treatment Related Adverse Events(TRAEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.003</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Allergies (Treatment).</title>
        <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without allergies is significant risk factor.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin With Allergies</title>
            <description>Participants with allergies who taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin Without Allergies</title>
            <description>Participants without allergies who taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for the Frequency of Treatment Related Adverse Events -Allergies (Treatment).</title>
          <description>Number of participants with Treatment Related Adverse Events(TRAEs) of Azithromycin to determine whether with or without allergies is significant risk factor.</description>
          <population>The safety analysis population consists of the cases that satisfy the cases conditions and in whom administration of this drug was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;Allergies&quot;. The null hypothesis is there is no difference between &quot;with and without allergies&quot; in the frequency of Treatment Related Adverse Events(TRAEs).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.707</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Responded to Azithromycin Treatment.</title>
        <description>The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The efficacy analysis population basically consists of the evaluable cases in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin for Treatment</title>
            <description>Participants taking Azithromycin for Treatment according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Responded to Azithromycin Treatment.</title>
          <description>The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results.</description>
          <population>The efficacy analysis population basically consists of the evaluable cases in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Prevented by Azithromycin Treatment.</title>
        <description>The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results.</description>
        <time_frame>9 years(MAX)</time_frame>
        <population>The efficacy analysis population basically consists of the evaluable cases in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin for Prophylaxis</title>
            <description>Participants taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Prevented by Azithromycin Treatment.</title>
          <description>The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results.</description>
          <population>The efficacy analysis population basically consists of the evaluable cases in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The frequency of treatment related advers events during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Azithromycin for Prophylaxis</title>
          <description>Participants taking Azithromycin for Prophylaxis according to Japanese Package Insert.</description>
        </group>
        <group group_id="E2">
          <title>Azithromycin for Treatment</title>
          <description>Participants taking Azithromycin for Treatment according to Japanese Package Insert.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA-J 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="391"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA-J 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="391"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Beta 2 microglobulin urine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="391"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="391"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

